Topchoice Medical Co., Inc. 600763.SS

CN · Shanghai Stock Exchange · XSHG · stock · Healthcare · website

Topchoice Medical Co., Inc. financials (annual)

Revenue

Net income

Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥2.9B	CN¥2.9B	CN¥2.8B	CN¥2.7B
Gross profit	CN¥1.1B	CN¥1.1B	CN¥1.1B	CN¥1.1B
R&D expense	CN¥61.2M	CN¥59.0M	CN¥55.6M	CN¥54.0M
SG&A expense	CN¥115.1M	CN¥114.6M	CN¥114.0M	CN¥107.0M
Operating income	CN¥713.9M	CN¥699.9M	CN¥705.2M	CN¥744.1M
Interest expense	CN¥35.8M	CN¥45.4M	CN¥55.0M	CN¥50.0M
Income tax	CN¥117.1M	CN¥121.9M	CN¥130.4M	CN¥122.3M
Net income	CN¥501.9M	CN¥501.0M	CN¥500.4M	CN¥548.3M
EPS (diluted)	CN¥1.12	CN¥1.12	CN¥1.12	CN¥1.22
Operating cash flow	CN¥810.7M	CN¥763.0M	CN¥841.0M	CN¥670.0M
Free cash flow	CN¥564.5M	CN¥430.9M	CN¥332.1M	CN¥248.5M
Cash & equivalents	CN¥696.3M	CN¥620.6M	CN¥594.5M	CN¥630.3M
Inventory	CN¥19.8M	CN¥30.0M	CN¥24.8M	CN¥22.9M
Goodwill	CN¥73.1M	CN¥73.1M	CN¥50.3M	CN¥50.3M
Total assets	CN¥6.0B	CN¥6.2B	CN¥6.1B	CN¥5.2B
Total debt	CN¥1.1B	CN¥1.4B	CN¥1.4B	CN¥1.2B
Total liabilities	CN¥1.5B	CN¥1.9B	CN¥1.9B	CN¥1.5B
Shareholders' equity	CN¥4.2B	CN¥4.0B	CN¥3.8B	CN¥3.3B

Growth · year-over-year · Revenue CAGR 2.3%

Metric	FY2025	FY2024	FY2023	FY2022
Revenue growth	+1.4%	+1.0%	+4.7%	—
Net income growth	+0.2%	+0.1%	-8.7%	—
EPS growth	+0.0%	+0.0%	-8.3%	—
Free cash flow growth	+31.0%	+29.7%	+33.6%	—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.